CTLA-4 Blockade of Natural Killer Cells Increases Cytotoxicity against Acute Lymphoid Leukaemia Cells Neda
Objective: There is interest in using cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy to treat blood cancers.Unfortunately, patients with acute lymphoblastic leukaemia (ALL) frequently exhibit resistance to treatment and naturalkiller (NK) cell exhaustion. This study aims to increase the cyt...
Main Authors: | Neda Parvini, Mohammad Esmaeil Akbari, Amir Ali Hamidieh, Fardin Fathi, Abbas Ali Amini, Marzieh Ebrahimi, Zakaria Vahabzadeh |
---|---|
Format: | Article |
Language: | English |
Published: |
Royan Institute (ACECR), Tehran
2024-02-01
|
Series: | Cell Journal |
Subjects: | |
Online Access: | https://www.celljournal.org/article_710008_7d80dc9dae311eeda26d9759146ed7bc.pdf |
Similar Items
-
Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
by: Fei Tang, et al.
Published: (2018-04-01) -
The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology
by: Shashuang Zhang, et al.
Published: (2020-03-01) -
Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma
by: Ying Zhang, et al.
Published: (2022-08-01) -
Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells
by: Margherita Passariello, et al.
Published: (2020-08-01) -
A soluble form of CTLA-4 is present in serum of pediatric patients with acute lymphoblastic leukaemia
by: R. Simone, et al.
Published: (2011-01-01)